Analystreport

Regeneron (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at Cowen Inc. They now have a $350.00 price target on the stock, down previously from $400.00.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com